{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:55:41Z","timestamp":1787496941223,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40262-024-01386-z","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T05:01:52Z","timestamp":1719032512000},"page":"981-997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed\/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059"],"prefix":"10.1007","volume":"63","author":[{"given":"Jen-Hao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Pennesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Brivio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke C. J.","family":"Ammerlaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Chen-Santel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Bielorai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Star\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"D\u00edaz-de-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Rives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aengus","family":"O\u2019Marcaigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Engstler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Rubio-San-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Brethon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Plat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Dirksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Sramkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-8268","authenticated-orcid":false,"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(18)30909-4","volume":"20","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Atun R. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol. 2019;20:483\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30909-4.","journal-title":"Lancet Oncol"},{"key":"1386_CR2","unstructured":"World Health Organization. (\u200e2021)\u200e. CureAll framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives. World Health Organization. n.d. https:\/\/iris.who.int\/handle\/10665\/347370."},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/LEU.2009.257","volume":"24","author":"A M\u00f6ricke","year":"2010","unstructured":"M\u00f6ricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265\u201384. https:\/\/doi.org\/10.1038\/LEU.2009.257.","journal-title":"Leukemia"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541\u201352. https:\/\/doi.org\/10.1056\/NEJMra1400972.","journal-title":"N Engl J Med"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339. https:\/\/doi.org\/10.3324\/haematol.2020.247031.","journal-title":"Haematologica"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3324\/HAEMATOL.2015.131680","volume":"101","author":"T Oskarsson","year":"2016","unstructured":"Oskarsson T, S\u00f6derh\u00e4ll S, Arvidson J, Forestier E, Montgomery S, Bottai M, et al. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. 2016;101:68\u201376. https:\/\/doi.org\/10.3324\/HAEMATOL.2015.131680.","journal-title":"Haematologica"},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1182\/BLOOD.2019004043","volume":"136","author":"SP Hunger","year":"2020","unstructured":"Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136:1803\u201312. https:\/\/doi.org\/10.1182\/BLOOD.2019004043.","journal-title":"Blood"},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"10008","DOI":"10.1200\/JCO.2019.37.15_suppl.10008","volume":"37","author":"SR Rheingold","year":"2019","unstructured":"Rheingold SR, Ji L, Xu X, Devidas M, Brown PA, Gore L, et al. Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children\u2019s Oncology Group (COG) study. J Clin Oncol. 2019;37:10008. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.10008.","journal-title":"J Clin Oncol"},{"key":"1386_CR9","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.67.3301.","journal-title":"J Clin Oncol"},{"key":"1386_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023;41:1664\u20139. https:\/\/doi.org\/10.1200\/JCO.22.00642.","journal-title":"J Clin Oncol"},{"key":"1386_CR11","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","volume":"17","author":"AD Ricart","year":"2011","unstructured":"Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17:6417\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0486.","journal-title":"Clin Cancer Res"},{"key":"1386_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18:3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0582.","journal-title":"Mol Cancer Res"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/J.BMCL.2014.10.021","volume":"24","author":"H Bouchard","year":"2014","unstructured":"Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates: a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24:5357\u201363. https:\/\/doi.org\/10.1016\/J.BMCL.2014.10.021.","journal-title":"Bioorg Med Chem Lett"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/J.MOLIMM.2014.09.014","volume":"67","author":"B Shor","year":"2015","unstructured":"Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67:107\u201316. https:\/\/doi.org\/10.1016\/J.MOLIMM.2014.09.014.","journal-title":"Mol Immunol"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/EJH.12862","volume":"98","author":"S Thota","year":"2017","unstructured":"Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98:425\u201334. https:\/\/doi.org\/10.1111\/EJH.12862.","journal-title":"Eur J Haematol"},{"key":"1386_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/leu.2011.206","volume":"26","author":"JF de Vries","year":"2012","unstructured":"de Vries JF, Zwaan CM, De Bie M, Voerman JSA, den Boer ML, van Dongen JJM, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26:255\u201364. https:\/\/doi.org\/10.1038\/leu.2011.206.","journal-title":"Leukemia"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","volume":"62","author":"NN Shah","year":"2015","unstructured":"Shah NN, Stevenson MS, Yuan CM, Richards K, Delbrook C, Kreitman RJ, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:964\u20139. https:\/\/doi.org\/10.1002\/pbc.25410.","journal-title":"Pediatr Blood Cancer"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1126\/SCIENCE.3240341","volume":"240","author":"N Zein","year":"1988","unstructured":"Zein N, Sinha AM, Mcgahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:1198\u2013201. https:\/\/doi.org\/10.1126\/SCIENCE.3240341.","journal-title":"Science"},{"key":"1386_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"key":"1386_CR20","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","volume":"36","author":"E Pennesi","year":"2022","unstructured":"Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022;36:1516\u201324. https:\/\/doi.org\/10.1038\/s41375-022-01576-3.","journal-title":"Leukemia"},{"key":"1386_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O\u2019Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40:956\u201367. https:\/\/doi.org\/10.1200\/JCO.21.01693.","journal-title":"J Clin Oncol"},{"key":"1386_CR22","volume-title":"Besponsa (inotuzumab ozogamicin) prescribing information (USPI)","author":"US FDA, CDER","year":"2017","unstructured":"US FDA, CDER. Besponsa (inotuzumab ozogamicin) prescribing information (USPI). Philadelphia: Pfizer Wyeth Pharmaceuticals Inc.; 2017."},{"key":"1386_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/S10928-018-9614-9","volume":"46","author":"M Garrett","year":"2019","unstructured":"Garrett M, Ruiz-Garcia A, Parivar K, Hee B, Boni J. Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn. 2019;46:211\u201322. https:\/\/doi.org\/10.1007\/S10928-018-9614-9.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1386_CR24","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"E Brivio","year":"2021","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M, Malone A, D\u00edaz-de-Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137:1582\u201390. https:\/\/doi.org\/10.1182\/blood.2020007848.","journal-title":"Blood"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576\u201388. https:\/\/doi.org\/10.1002\/psp4.12224.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1386_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493\u2013507. https:\/\/doi.org\/10.2165\/11531280-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1386_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401\u201321. https:\/\/doi.org\/10.1007\/s10928-008-9094-4.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1386_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504. https:\/\/doi.org\/10.1023\/A:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/bja\/aer057","volume":"106","author":"AM Peters","year":"2011","unstructured":"Peters AM, Snelling HLR, Glass DM, Bird NJ. Estimation of lean body mass in children. Br J Anaesth. 2011;106:719\u201323. https:\/\/doi.org\/10.1093\/bja\/aer057.","journal-title":"Br J Anaesth"},{"key":"1386_CR30","doi-asserted-by":"publisher","first-page":"F632","DOI":"10.1152\/ajprenal.1984.247.4.F632","volume":"247","author":"P Boer","year":"1984","unstructured":"Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol Renal Physiol. 1984;247:F632\u20136. https:\/\/doi.org\/10.1152\/ajprenal.1984.247.4.F632.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2010.30.2307","volume":"28","author":"SS Ramalingam","year":"2010","unstructured":"Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol. 2010;28:4507\u201312. https:\/\/doi.org\/10.1200\/JCO.2010.30.2307.","journal-title":"J Clin Oncol"},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"1386_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"A-G Dosne","year":"2017","unstructured":"Dosne A-G, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44:509\u201320. https:\/\/doi.org\/10.1007\/s10928-017-9542-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/cts.12841","volume":"14","author":"J Chen","year":"2021","unstructured":"Chen J, Haughey M, Vandendries E, DeAngelo DJ, Kantarjian HM, Ruiz-Garcia A. Characterization of the relationship of inotuzumab ozogamicin exposure with efficacy and safety end points in adults with relapsed or refractory acute lymphoblastic leukemia. Clin Transl Sci. 2021;14:184\u201393. https:\/\/doi.org\/10.1111\/cts.12841.","journal-title":"Clin Transl Sci"},{"key":"1386_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part I: description of commands and options, with simple examples of population analysis. CPT Pharmacomet Syst Pharmacol. 2019;8:525\u201337. https:\/\/doi.org\/10.1002\/psp4.12404.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1386_CR36","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol. 2019;8:538\u201356. https:\/\/doi.org\/10.1002\/psp4.12422.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1386_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Programs Biomed"},{"key":"1386_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72\u20139. https:\/\/doi.org\/10.1016\/j.cmpb.2010.04.018.","journal-title":"Comput Methods Programs Biomed"},{"key":"1386_CR39","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52:1918\u201326. https:\/\/doi.org\/10.1177\/0091270011430506.","journal-title":"J Clin Pharmacol"},{"key":"1386_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40262-018-0694-x","volume":"58","author":"JC Masters","year":"2019","unstructured":"Masters JC, Barry E, Knight B. Population pharmacokinetics of gemtuzumab ozogamicin in pediatric patients with relapsed or refractory acute myeloid leukemia. Clin Pharmacokinet. 2019;58:271\u201382. https:\/\/doi.org\/10.1007\/s40262-018-0694-x.","journal-title":"Clin Pharmacokinet"},{"key":"1386_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2141.2009.07701.x","volume":"146","author":"A Takeshita","year":"2009","unstructured":"Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol. 2009;146:34\u201343. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07701.x.","journal-title":"Br J Haematol"},{"key":"1386_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ejca.2005.09.017","volume":"42","author":"K Swerts","year":"2006","unstructured":"Swerts K, De MB, Dhooge C, Laureys G, Benoit Y, Philipp\u00e9 J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer. 2006;42:295\u2013309. https:\/\/doi.org\/10.1016\/j.ejca.2005.09.017.","journal-title":"Eur J Cancer"},{"key":"1386_CR43","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1182\/blood.V91.6.2092","volume":"91","author":"ML den Boer","year":"1998","unstructured":"den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, et al. Relationship between major vault protein\/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998;91:2092\u20138. https:\/\/doi.org\/10.1182\/blood.V91.6.2092.","journal-title":"Blood"},{"key":"1386_CR44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/cancers12020303","volume":"12","author":"F Lanza","year":"2020","unstructured":"Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F. CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers (Basel). 2020;12:303. https:\/\/doi.org\/10.3390\/cancers12020303.","journal-title":"Cancers (Basel)."},{"key":"1386_CR45","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1080\/10428194.2020.1786553","volume":"61","author":"CD Godwin","year":"2020","unstructured":"Godwin CD, Bates OM, Jean SR, Laszlo GS, Garling EE, Beddoe ME, et al. Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia. Leuk Lymphoma. 2020;61:2990\u20134. https:\/\/doi.org\/10.1080\/10428194.2020.1786553.","journal-title":"Leuk Lymphoma"},{"key":"1386_CR46","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood.2020008544","volume":"137","author":"H Kirchhoff","year":"2021","unstructured":"Kirchhoff H, Karsli U, Schoenherr C, Battmer K, Erschow S, Talbot SR, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021;137:2657\u201361. https:\/\/doi.org\/10.1182\/blood.2020008544.","journal-title":"Blood"},{"key":"1386_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","volume":"2018","author":"KG Roberts","year":"2018","unstructured":"Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology. 2018;2018:137\u201345. https:\/\/doi.org\/10.1182\/asheducation-2018.1.137.","journal-title":"Hematology"},{"key":"1386_CR48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0091270004267595","volume":"44","author":"M Buckwalter","year":"2004","unstructured":"Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44:873\u201380. https:\/\/doi.org\/10.1177\/0091270004267595.","journal-title":"J Clin Pharmacol"},{"key":"1386_CR49","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","volume":"24","author":"DC Turner","year":"2018","unstructured":"Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, et al. Pembrolizumab exposure\u2013response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018;24:5841\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0415.","journal-title":"Clin Cancer Res"},{"key":"1386_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29939","volume":"70","author":"D McCall","year":"2023","unstructured":"McCall D, Jabbour E, Roth M, Nunez C, Cuglievan B. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023;70: e29939. https:\/\/doi.org\/10.1002\/pbc.29939.","journal-title":"Pediatr Blood Cancer"},{"key":"1386_CR51","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1200\/JCO.2023.41.16_suppl.10016","volume":"41","author":"MM O\u2019Brien","year":"2023","unstructured":"O\u2019Brien MM, McNeer JL, Rheingold SR, Devidas M, Chen Z, Bhojwani D, et al. A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: second safety phase results from Children\u2019s Oncology Group AALL1732. J Clin Oncol. 2023;41:10016. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.10016.","journal-title":"J Clin Oncol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01386-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T12:11:23Z","timestamp":1721477483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01386-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01386-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"19 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ITCC-059 was sponsored by Erasmus MC and financed by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Susana Rives reports honoraria and\/or travel support from Novartis, Servier, Celgene\/Bristol Myers Squibb, Kite\/ Gilead, Pfizer, and Amgen. Susana Rives reports being part of a Date and Safety Monitoring Board (DMSB) in a clinical trial sponsored by Novartis and of a data monitoring committee in a clinical trial sponsored by Autolus. Alwin D.R. Huitema is an Editorial Board member of <i>Clinical Pharmacokinetics<\/i>. Alwin D.R. Huitema was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Francisco Bautista is a member of a data monitoring committee for a clinical trial sponsored by Sanofi, had a consultant or advisory role for Bayer, Amgen, Roche Genentech, and EusaPharma and received honoraria for speaking at symposia from Roche Genentech. Claudia Rossig has received honoraria from BMS, Amgen, Novartis, Pfizer, and Roche Genentech. Franco Locatelli has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen, Miltenyi, Jazz Pharmaceutical, Medac, Neovii, Novartis, Sanofi, Sobi, Vertex, and Gilead. Alba Rubio-San-Sim\u00f3n had a consulting role for Eusa Pharma, Sanofi, and SERB, and has received honoraria from Eusa Pharma and Roche for educational events and travel expenses. Gernot Engstler has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Servier. C. Michel Zwaan reports serving as a consultant\/advisory board member for Incyte, Takeda, Johnson&Johnson, Sanofi, Syndax, Bristol Meyers Squibb, Roche, Kura Oncology Inc., Novartis, Pfizer, AbbVie, Daiichi Sankyo, Servier, and Astra Zeneca, and has received institutional funding from Pfizer, Daiichi Sankyo, Takeda, AbbVie, Jazz Pharma, and Kura Oncology. May Garrett is an employee of and owns stock in Pfizer Inc. Kei Fukuhara is an employee of Pfizer Japan Inc. and owns stock in Pfizer Inc. Jen-Hao Wu, Edoardo Pennesi, Francisco Bautista, Erica Brivio, Anneke C.J. Ammerlaan, Inge M. van der Sluis, C. Michel Zwaan, and Alwin D.R. Huitema report institutional funding from Pfizer for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from each participant before conducting any study procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consent was obtained from participants in this trial.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Anonymized data are available in consultation with the sponsor and subject to review.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study conception and design: CMZ and Pfizer Inc. through the development of the Pediatric Investigational Plan and its approval by the Paediatric Committee (PDCO) of the European Medicines Agency. Data collection and patient management: CMZ, ACJA, EP, EB, SR, FL, IMVDS, CR, CCS, BB, AP, JS, CDH, AO, CR, GE, KN, ARSS, BB, YB, BB, FR, GP, UD, LS. Data analysis and interpretation: CMZ, ADRH, JW, EB, EP, FB, MG, KF. Manuscript writing: all authors critically made a substantial contribution in writing the paper, reviewed the manuscript, and approved the final version for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}